2027 ICD-10-CM Diagnosis Code J70.2Acute drug-induced interstitial lung disorders
ICD-10-CM Codes›J00–J99›J60-J70›J70
- Billable — Valid for Submission
- Not Chronic
J70.2 is a billable ICD-10-CM diagnosis code for acute drug-induced interstitial lung disorders. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 205 through 206. Coders also document this condition as acute drug-induced interstitial lung disorder. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Drug induced or toxic related condition and Lung disease due to external agents.
J70.2 no longer risk-adjusts for Medicare Advantage: it mapped to HCC 112 under the retired CMS-HCC V24 model through payment year 2025 but maps to no category in the live V28 model. It still risk-adjusts in the PACE (CMS-HCC V22) category 112, ESRD (V21) category 112, and ESRD (V24) category 112 for payment year 2027.
Code Identity
Code Classification
Medicare Risk Adjustment (HCC)Billing
J70.2 no longer risk-adjusts for Medicare Advantage: it maps to no payment category in the live CMS-HCC V28 model, although it still risk-adjusts in the other CMS models shown below.
Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Acute drug-induced interstitial lung disorder
Instructional NotesGuidance
Instructions from the official ICD-10-CM Tabular List that apply to J70.2: its own notes plus those printed at block J60-J70 and Chapter 10. A note printed at a category, block or chapter applies to every code under it.
Excludes1
Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.
Excludes2
Not included here: the excluded condition is not part of this code, but a patient may have both, so both codes may be reported.
- certain conditions originating in the perinatal period (P04-P96)
- certain infectious and parasitic diseases (A00-B99)
- complications of pregnancy, childbirth and the puerperium (O00-O9A)
- congenital malformations, deformations and chromosomal abnormalities (Q00-Q99)
- endocrine, nutritional and metabolic diseases (E00-E88)
- injury, poisoning and certain other consequences of external causes (S00-T88)
- neoplasms (C00-D49)
- smoke inhalation (T59.81-)
- symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R00-R94)
Use Additional Code
Add a second code, after this one, to fully describe the condition.
Notes
General instructions on how these codes are used.
- When a respiratory condition is described as occurring in more than one site and is not specifically indexed, it should be classified to the lower anatomic site (e.g. tracheobronchitis to bronchitis in J40).
Source: CMS ICD-10-CM Tabular List. How to read instructional notes.
Referenced in Other NotesGuidance
Instructional notes printed at other codes that name J70.2, its category, or a range that includes it.
Excludes1 3
These codes carry an Excludes1 note naming J70.2: they are not reported together with it, unless the two conditions are unrelated.
Excludes2 6
These codes carry an Excludes2 note naming J70.2: its condition is not part of those codes, and both may be reported when the patient has both.
Code First 1
These codes say to code first a condition named in the note, and J70.2 is one of the conditions named.
- J84.170 Interstitial lung disease with progressive fibrotic phenotype in diseases classified elsewhere
Use Additional Code 1
These codes say to use an additional code from the note, and J70.2 is one of the codes named.
- Block T51-T65 Toxic effects of substances chiefly nonmedicinal as to source
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
Disorder (of) See Also: Disease;
Pneumonitis (acute) (primary) See Also: Pneumonia; J98.4
acute J70.2
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Patient EducationClinical
Drug Reactions
Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.
The full article covers:
- What is a drug interaction?
- What are side effects?
- What are drug allergies?
- How can I stay safe when taking medicines?
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert J70.2 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About J70.2Overview
What is the ICD-10 code for acute drug-induced interstitial lung disorders?
The ICD-10-CM code for acute drug-induced interstitial lung disorders is J70.2 (sometimes written as J702). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
Is J70.2 (Respiratory conditions due to other external agents) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report acute drug-induced interstitial lung disorders on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
What MS-DRG does J70.2 group to?
When acute drug-induced interstitial lung disorders is the principal diagnosis on an inpatient stay, it groups to MS-DRG 206, 205, with relative weights from 0.9255 to 1.8244 depending on complications. Higher weights mean higher Medicare reimbursement.
Can J70.2 be reported with J84.9?
Not as a rule. The Excludes1 note on J70.2 lists "interstitial pneumonia NOS (J84.9)". An Excludes1 note means the excluded code is never reported together with this one; the only exception is when the two conditions are unrelated to each other (Official Guidelines, Section I.A.12.a).
Does J70.2 need an additional code?
When the condition applies, yes. The Use Additional Code note reads: code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5). The additional code is reported after J70.2.
Does J70.2 risk-adjust for Medicare Advantage payment?
Not for Medicare Advantage. J70.2 mapped to HCC 112 in the retired CMS-HCC V24 model, which last determined payment in 2025, but it maps to no category in the live V28 model; see all codes that no longer risk-adjust. It still risk-adjusts in the PACE (CMS-HCC V22) category 112 (Fibrosis of Lung and Other Chronic Lung Disorders), ESRD (V21) category 112 (Fibrosis of Lung and Other Chronic Lung Disorders), and ESRD (V24) category 112 (Fibrosis of Lung and Other Chronic Lung Disorders).
